Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer.
BACKGROUND
Mammary cancer has a high incidence in canines and is an excellent model of spontaneous carcinogenesis. Molecular iodine (I2) exerts antineoplastic effects on different cancer cells activating re-differentiation pathways. In co-administration with anthracyclines, I2 impairs chemoresistance installation and prevents the severity of side effects generated by these antineoplastic drugs. This study is a random and double-blind protocol that analyzes the impact of I2 (10 mg/day) in two administration schemes of Doxorubicin (DOX; 30 mg/m2) in 27 canine patients with cancer of the mammary gland. The standard scheme (sDOX) includes four cycles of DOX administered intravenously for 20 min every 21 days, while the modified scheme (mDOX) consists of more frequent chemotherapy (four cycles every 15 days) with slow infusion (60 min). In both schemes, I2 or placebo (colored water) was supplemented daily throughout the treatment.


RESULTS
mDOX attenuated the severity of adverse events (VCOG-CTCAE) in comparison with the sDOX group. The overall tumor response rate (RECIST criteria) for all dogs was 18% (interval of reduction 48-125%), and no significant difference was found between groups. I2 supplementation enhances the antineoplastic effect in mDOX, exhibiting a significant decrease in the tumor epithelial fraction, diminished expression of chemoresistance (MDR1 and Survivin) and invasion (uPA) markers and enhanced expression of the differentiation factor known as peroxisome proliferator-activated receptors type gamma (PPARγ). Significant tumor lymphocytic infiltration was also observed in both I2-supplemented groups. The ten-month survival analysis showed that the entire I2 supplementation (before and after surgery) induced 67-73% of disease-free survival, whereas supplementation in the last period (only after surgery) produced 50% in both schemes.


CONCLUSIONS
The mDOX+I2 scheme improves the therapeutic outcome, diminishes the invasive capacity, attenuates the adverse events and increases disease-free survival. These data led us to propose mDOX+I2 as an effective treatment for canine mammary cancer.
['Zambrano-Estrada|Xóchitl|X|', 'Landaverde-Quiroz|Brianda|B|', 'Dueñas-Bocanegra|Andrés A|AA|', 'De Paz-Campos|Marco A|MA|', 'Hernández-Alberto|Gerardo|G|', 'Solorio-Perusquia|Benjamín|B|', 'Trejo-Mandujano|Manuel|M|', 'Pérez-Guerrero|Laura|L|', 'Delgado-González|Evangelina|E|', 'Anguiano|Brenda|B|', 'Aceves|Carmen|C|http://orcid.org/0000-0001-9418-8304']
D000818:Animals D000970:Antineoplastic Agents D004283:Dog Diseases D004285:Dogs D004317:Doxorubicin D005260:Female D007455:Iodine D015674:Mammary Neoplasms, Animal D020360:Neoadjuvant Therapy
Molecular iodine Doxorubicin Canine mammary cancer Animal welfare Neoadjuvant chemotherapy